Page 40 - IACC Newsletter June 2013 Issue 11

Basic HTML Version

Starbucks® entered the Indian market in October 2012 and currently operates fifteen stores in India. These include
seven stores in Mumbai, one store at Mumbai's Chhatrapati Shivaji Airport, five stores in New Delhi and two stores at
the New Delhi Indira Gandhi International Airport. Starbucks® stores are operated by the joint venture, Tata Starbucks
Limited, and branded as Starbucks Coffee - "A Tata Alliance".
About Starbucks
Since 1971, Starbucks Coffee Company has been committed to ethically sourcing and roasting the highest-quality arabica
coffee in the world. Today, with more than 17,000 stores around the globe, the company is the premier roaster and
retailer of specialty coffee in the world. "Through our unwavering commitment to excellence and our guiding principles,
we bring the unique Starbucks Experience to life for every customer through every cup. To share in the experience,
please visit us in our stores or online at"
About Tata Global Beverages
Tata Global Beverages is a part of the global Tata Group. Tata Global Beverages is a global beverage business and the
world's second largest tea company. The group's annual turnover is US $1.5 billion and it employs around 3000 people
worldwide. The Company focuses on 'good for you' beverages and has a stable of innovative regional and global
beverage brands , including Tata Tea, Tetley, Himalayan natural mineral water and Eight O' Clock Coffee.
Cadila's prospects hinge on US growth
New drug discovery will add substantially to domestic revenues over a year's time, while US product launches, growth
remains essential to drive earnings & margins in near term.
Cadila Healthcare’s announcement for approval of India’s first Novel Chemical entity comes as a cool breeze for the
pharma Industry. It comes at a time when the Indian Pharma Industry has been embarrassed by the issues as those of
Ranbaxy followed by Wockhardt also getting an import alert from the USFDA. The drug discovery is indeed an
achievement for Cadila, which has pioneered a molecule, “becoming first Indian company ever to do so.
Furthermore, Cadila derives pride from the fact that the molecule used for treating Diabetes as well as having
Cholesterol lowering abilities is also the first in its own class of drugs (Glitazars) to be approved in the world. It has
beaten a number of companies who are doing research on Glitazars around the world.
The development should instigate strong confidence in investors for the company that has underperformed for some
time on the bourses. The underperformance has been on the back of lower-than-expected ramp-up in US revenues.
With US growth being a drag, the margins, too, have suffered.
However, this can change if the company gets the required approvals in the US during FY14. Doing this, margins, too,
can improve. The newly discovered product to be launched in second half of FY14 will start providing some support to
the domestic revenues though material benefits will flow in FY15.
Pioneering a breakthrough
Zydus Cadila’s research molecule. “seroglitazar’ to be marketed under brand name 'Lipaglyn' providing dual benefits of
treating diabetes (Glycemia) as well as reduction of Cholesterol is likely to be launched in December’13 quarter. Mr
Pankaj R Patel, Chairman and MD Cadila expect the product to become a Rs 100-crore brand in India in next three years.
The company after getting approvals in India is going to file for approvals in the US as well as other geographies. The
product has been developed over a period of 13 years at an investment of around $250 million. The company is planning
to invest around $100 million more in the process of getting approvals in developed markets and other countries said Mr